

Tuning the Loading and Release Properties of MicroRNA-Silencing Porous Silicon Nanoparticles by Using Chemically Diverse Peptide Nucleic Acid Payloads

Martina Neri, Jinyoung Kang, Jonathan M. Zuidema, Jessica Gasparello, Alessia Finotti, Roberto Gambari, Michael J. Sailor, Alessandro Bertucci,* and Roberto Corradini



Cite This: *ACS Biomater. Sci. Eng.* 2022, 8, 4123–4131



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: Peptide nucleic acids (PNAs) are a class of artificial oligonucleotide mimics that have garnered much attention as precision biotherapeutics for their efficient hybridization properties and their exceptional biological and chemical stability. However, the poor cellular uptake of PNA is a limiting factor to its more extensive use in biomedicine; encapsulation in nanoparticle carriers has therefore emerged as a strategy for internalization and delivery of PNA in cells. In this study, we demonstrate that PNA can be readily loaded into porous silicon nanoparticles (pSiNPs) following a simple salt-based trapping procedure thus far employed only for negatively charged synthetic oligonucleotides. We show that the ease and versatility of PNA chemistry also allows for producing PNAs with different net charge, from positive to negative, and that the use of differently charged PNAs enables optimization of loading into pSiNPs. Differently charged PNA payloads determine different release kinetics and allow modulation of the temporal profile of the delivery process. *In vitro* silencing of a set of specific microRNAs using a pSiNP-PNA delivery platform demonstrates the potential for biomedical applications.

KEYWORDS: oligonucleotide mimics, drug delivery, anti-microRNA therapeutics, nanomaterials, release kinetics



Peptide nucleic acids (PNAs) are artificial oligonucleotide mimics that have gathered much attention over the last decades for their potential as therapeutic agents and as tools for molecular diagnostics.^{1,2} The absence of electrostatic charge due to a N-(2-aminoethyl)glycine backbone makes the hybridization of PNAs with complementary DNA or RNA strands more favorable than that between natural oligonucleotides.³ The presence of this unnatural backbone is also why PNAs have exceptional biological stability: in contrast to natural nucleic acids and peptides, they are not recognized and degraded by nucleases and proteases. Another crucial feature of PNAs is that by using standard solid-phase manual or automated synthesis⁴ typical of peptide synthesis, PNA monomers can be easily assembled and conjugated with a range of diverse functional groups, such as fluorophores, amino acids, or small molecules. These properties have all been harnessed to exploit the use of PNAs in a wide range of biomedical applications, from precision medicine therapeutics to chemical biology to molecular diagnostics.^{5,6} However, the uncharged nature of the PNA backbone also generates limitations—it can result in low water solubility compared to DNA and RNA and low cellular internalization in drug delivery applications. Several strategies to overcome these issues have been pursued.⁷ Some of the most promising approaches

involve conjugation with cell-penetrating peptides,^{8–12} or formulation with liposomes,^{13–15} polymer nanoparticles,^{16–21} and carbon-based nanocarriers.^{22–25} Porous inorganic nanocarriers have also been demonstrated to be particularly suited for the loading and the delivery of PNA.^{26–28} Among these, porous silicon nanoparticles (pSiNPs) have emerged as a class of nanomaterials with a suite of properties that makes them especially amenable to accommodating and releasing biomolecular payloads. The intrinsic photoluminescence, the biocompatibility, and the biodegradability of porous silicon structures enable their use as drug delivery platforms for *in vivo* applications.^{29–31} Porous silicon nanomaterials are fabricated via electrochemical anodization of single crystalline silicon wafers in hydrofluoric acid solution. The advantage of this electrochemical synthesis procedure lies in the high degree of control it exerts over the morphological properties of the pSi

Special Issue: Advances on Porous Nanomaterials for Biomedical Application (Drug Delivery, Sensing, and Tissue Engineering)

Received: March 30, 2021

Accepted: August 11, 2021

Published: September 1, 2021






Figure 1. Preparation and characterization of Ca-pSiNPs-PNA. (A) Pictorial representation of a neutral PNA oligomer that can be conjugated to differently charged amino acid residues. (B) Schematic representation of the calcium silicate trapping protocol used to produce PNA-loaded pSiNPs. (C) ζ -Potential measurements of oxidized pSiNPs and pSiNPs loaded with PNA, PNA-E8, and PNA-R8, respectively, following salt-based trapping using calcium silicate (mean \pm SD, $n = 3$). (D) Transmission electron microscope (TEM) image of freshly etched pSiNPs (scale bar = 200 nm); the inset shows a close-up of a single particle (scale bar = 100 nm). (E) TEM image of calcium silicate-capped pSiNP-PNA complexes (scale bar = 200 nm); the inset shows a close-up of a single particle (scale bar = 100 nm).

material, such as pore size, thickness, and porosity, simply by varying the experimental and instrumental parameters.³² In addition, the surface of porous silicon materials, which naturally tends to present a thin layer of silicon oxide if left untreated after synthesis, can be conveniently modified with different groups and molecules by exploiting currently available strategies based on silane chemistry. This also plays a key role in regulating the dissolution rate of pSiNPs in aqueous media and therefore in the release of payloads in biological settings. All these features make pSiNPs attractive delivery vehicles for PNA. However, interfacing PNA with pSiNPs is not a trivial task, because the uncharged nature of PNA prevents the use of conventional loading strategies based on electrostatic adsorption of anionic oligonucleotides. In 2014, a first work explored *in situ* synthesis of PNA on pSi supports and showed that this strategy could afford a loading value of 8.6×10^{-4} mol PNA/g pSi and a sustained release in aqueous buffer.³³ These pSiNP-PNA complexes enabled the delivery of specific anti-microRNA (anti-miR) PNA sequences in human hepatic carcinoma cells. Beavers et al. deployed an endosomolytic two-block polymer as a coadjuvant for the encapsulation of PNA in pSiNPs. This approach allowed highly efficient loading of PNA, and polymer-pSiNP composites were used to deliver anti-microRNA PNA sequences *in vivo*.³⁴ However, using a polymer-based formulation in tandem with pSiNPs requires additional synthetic effort and an increase in the number of components in the final formulation, which may hinder clinical translation. In this study, we establish a simpler and more expedited means to encapsulate PNA in pSiNPs that achieves highly efficient loading and enables fine-tuning of the temporal properties of payload release. Our approach leverages the

chemical versatility of PNA, which, different from other oligonucleotide analogues, can be synthesized with a user-defined net charge, and a single-step salt-based loading technique that requires neither adjuvants nor derivatization reactions at the nanoparticle surface. Here, we encapsulated a small library of differently charged PNAs into pSiNPs and demonstrated that the chemical–physical nature of the PNA payload determines its release kinetics in aqueous buffer. Importantly, we show that pSiNPs-PNA complexes fabricated in this way hold promise as a nanomedicine platform, as we demonstrate their use *in vitro* for the delivery of anti-miR PNAs in human bronchial epithelial cells.

Recently, a new procedure for loading of small interfering RNA (siRNA) into pSiNPs was developed in the Sailor group. This is based on physical trapping of the synthetic oligonucleotides in the pores of the particles caused by the simultaneous precipitation of an insoluble shell of calcium silicate Ca_2SiO_4 at the particle surface.³⁵ This method enabled loading of a considerable amount of siRNA in the particles in the range 20–25% by mass and allowed efficient payload release *in vivo*. The presence of the calcium silicate coating causes a slower release of the siRNA payload compared to formulations based on electrostatic interactions, because the pSi skeleton is prevented from an early dissolution in aqueous media.³⁵ The same method was then employed for the loading and delivery of synthetic LNA,³⁶ DNA,³⁷ and RNA payloads,^{38–40} which all capitalize on the negatively charged phosphate-based backbone of the synthetic oligonucleotides. Motivated by the simplicity and the efficacy of this approach, we set out to explore its extension to PNA payloads. For this, we have engineered a small library of PNAs with different net

charge, which would allow us to systematically study how varying this property could modulate the efficiency of the above trapping process. For this study, we have selected three different PNA sequences: PNA1: H-TTTCGTTATTGCTCT-TGA-Gly-NH₂, PNA2: H-AGTTATCACAGTACTGTA-Gly-NH₂, PNA3: H-AGGGATTCCCTGGGAAAAC-Gly-NH₂. These sequences are complementary to three specific microRNAs, i.e., miR-335, miR-101, and miR-145, respectively, and may be potential candidates in microRNA-silencing therapeutic strategies for cystic fibrosis.^{41–43} PNAs can be easily modified and diversified by introducing chemical variations at both the backbone and the nucleobase level or through the conjugation with amino acids along the strand. To obtain a set of differently charged PNAs, we conjugated each sequence at the N-terminus to either eight arginine (PNA-R8) or glutamic acid residues (PNA-E8) (Figure 1A). The synthesis was carried out manually following a standard Fmoc-based solid-phase synthesis (SPS) protocol, and the products were all purified by RP-HPLC and characterized by means of ESI-MS (Figure S1–S9, Supporting Information, SI). pSiNPs were produced by electrochemical etching of highly boron-doped p⁺ single-crystal silicon wafers in a hydrofluoric acid electrolyte following a well-established “perforation” procedure.³² The as-etched nanoparticles were characterized by transmission electron microscopy (TEM) (Figure 1D), and their hydrodynamic radius was found to be 215 ± 8 nm by dynamic light scattering (DLS) (Figure S10A, SI). The porous layer porosity was measured to be 58% ± 4% by a nondestructive spectroscopic liquid infiltration method (SLIM).⁴⁴ Cryogenic nitrogen adsorption isotherm using the Brunauer–Emmett–Teller (BET) method allowed determination of a total pore volume of 1.33 cm³ g⁻¹, a surface area of 370.5 m² g⁻¹, and an average pore size of 14.5 nm (Figure S12). Such pore size, together with the above particle size, is well-fit for accommodating a macromolecule such as PNA. Oxidized pSiNPs were then loaded with the differently charged PNAs following a calcium silicate trapping procedure in the presence of a high concentration (4 M) of calcium chloride (CaCl₂) (Figure 1B). This procedure allows mechanical entrapment of the oligonucleotides within the pores of the particles due to the precipitation of calcium silicate Ca₂SiO₄ at the nanoparticle surface (Figures 1E and S11, SI). The three formats of neutral, negative, and positive PNA were, respectively, added (final concentration 15 μM) to a dispersion of pSiNPs in ethanol (1 mg/mL) in the presence of CaCl₂ and incubated for 45 min. Calcium silicate-based trapping of PNA led to a slight increase in the average hydrodynamic diameter of the nanoparticles (up to ~270 nm) and a shift in the ζ-potential to less negative values (Figure 1C). Interestingly, we registered negative values of ζ-potential for all three classes of PNA. This suggests that the trapping procedure results in an efficient encapsulation of the different PNA payloads in the nanoparticle pores, and the final surface charge of the loaded nanoparticles is only determined by the presence of the calcium silicate coating formed. This is particularly evident in the case of positively charged PNA (Figure 1C). PNA loading (defined as the mass of the oligonucleotide divided by the total mass of the oligonucleotide + Si nanoparticles) was quantified by UV–vis spectroscopy measurements of the supernatants at λ = 260 nm.

The loading values were calculated to be ~17% w/w for all the positively charged (PNA_x-R8) and negatively charged (PNA_x-E8) PNAs tested, irrespective of their sequence

composition. The use of neutral PNAs led to a lower loading of ~8% w/w. This result could be ascribed to the complete lack of charge in the neutral PNA, which may determine a lower solubility in the working solution and/or may not provide any significant driving force to the encapsulation process, as no electrostatic interactions occur between the oligonucleotide, the nanoparticles, and the calcium-pSi layer. The loading values calculated for the entire set of PNA payloads tested are reported in Table 1, where loading is also

Table 1. Loading of Different PNA Payloads

PNA payload	loading (nmol/mg)	loading value (%)
PNA 1- R8	29 ± 3	17.6
PNA 1- E8	30 ± 1	17.7
PNA 1	16.4 ± 0.8	8.7
PNA 2- R8	27 ± 2	16.7
PNA 2- E8	29.7 ± 0.3	17.7
PNA 2	16 ± 4	8.7
PNA 3- R8	27 ± 2	16.7
PNA 3- E8	29.2 ± 0.7	17.7
PNA 3	16 ± 4	8.8

expressed in terms of nanomoles of PNA divided by milligrams of pSiNPs. Beavers et al. reported loading values of 20 nmol/mg for neutral PNA in pSiNP–polymer nanocomposite.³⁴ In this present case, PNA loading of ~30 nmol/mg and ~29 nmol/mg was achieved with negatively charged and positively charged PNAs, respectively, without the use of a coadjuvant polymer. We also note that our method enables loading of neutral, unmodified PNA in pSiNPs in a very simple way, although with a lower efficiency when compared to charged PNAs. The above loading values correspond to loading efficiencies (PNA nmol encapsulated/PNA nmol incubated) of 98.7% ± 0.4%, 96% ± 3%, and 64% ± 2% for PNA-E8, PNA-R8, and PNA, respectively (Figure S13, SI). Next, we systematically studied the release kinetics of pSiNP systems loaded with differently charged PNAs. Release of PNA from the calcium silicate-sealed nanoparticles was achieved by incubation in aqueous phosphate buffered saline (PBS), pH 7.4 at 37°, which simulates physiological conditions. The concentration of PNA released into the solution at specific time points was determined by measuring its UV–vis absorbance intensity (λ = 260 nm). Three distinct release profiles were obtained based on the net charge of the PNA payload. The release profile of the anionic PNA-E8 (Figure 2A) is characterized by a rapid kinetics, leading to a burst release of ~95% of the total PNA-E8 loaded within the nanoparticles in the first 2 h. This is comparable to the degradation profile reported for Ca-pSiNPs loaded with locked nucleic acid (LNA) and siRNA.^{35,36} Nearly 100% efficiency release (defined as mass of released PNA divided by mass of loaded PNA) was observed in this case (Figure S13, SI). pSiNPs loaded with cationic PNA-R8 showed a slower release kinetics compared the previous pSiNP-PNA-E8-complexes (Figure 2B,D,E). In this case, nearly 80% of the loaded PNA-R8 was released within the first 8 h and 95% over 24 h (Figure 2B). Nearly quantitative release of the PNA-R8 payload was observed within 24 h (Figure S13, SI). The release kinetics of pSiNPs loaded with neutral PNA showed another different, slower temporal profile compared to PNA-R8 and PNA-E8. No major burst release was observed in this case, with an average of 55% of the total PNA loaded from Si




Figure 2. Release kinetics of pSiNPs loaded with differently charged PNA payloads. Cumulative release % of PNA-E8 (A), PNA-R8 (B), and PNA (C) over 48 h (mean \pm SD, $n = 3$). The fractional quantity of PNA released from pSiNPs shows a faster release kinetics for anionic PNA-E8 followed by cationic PNA-R8 and neutral PNA. Relative PNA release was normalized to the same scale, where 1.0 equals to the total amount of PNA released in 48 h (D). Three distinct release rates are expressed as release efficiency (defined as mass of released PNA divided by mass of loaded PNA) at the 2 h time point (E).

nanoparticles released in the first 8 h. We assume that the absence of electrostatic interactions between the nanoparticles and the oligonucleotide cargo may play a crucial role in its release kinetics. Contrary to the first two cases, the neutral PNA payload was released with an efficiency of $\sim 64\%$ (Figure S13, SI). It is possible that the absence of electrostatic interactions due to the neutral nature of the PNA payload may cause a slower release kinetics and a more difficult degradation process when compared to the use of negatively or positively charged PNAs. Ion exchange processes normally contribute to the release of charged payloads from nanoparticle carriers.^{26,45}

In addition, all the final Ca-pSiNPs-PNA complexes displayed a net negative charge on their surface as demonstrated by the ζ -potential measurements, and this may accelerate the release kinetics of negatively charged PNA because of electrostatic repulsion at the interface once the degradation of the particles has started. Electrostatic interactions and ion exchange mechanisms are missing when using a neutral PNA, which may cause the release kinetics to be exclusively associated with the degradation of the nanoparticles. The distinct release rate characterizing the three different formulations is demonstrated by the release efficiency (PNA released/PNA loaded) observed after 2 h in each specific case, which shows that pSiNPs release the anionic payload PNA-E8 2-fold and ~ 7 -fold faster than cationic PNA-R8 and neutral PNA, respectively (Figure 2E). The difference in the release rate of the three formulations suggests that PNA delivery tuned in time may be achieved by playing on the net charge of the specific PNA payload used. To expand the application window of our method, we also demonstrated that combined loading and release of two PNAs with different sequences is readily obtainable. As a proof-of-principle demonstration, we set out to coload and release two

PNAs bearing different sequences. A preliminary experiment was performed using the two negative PNAs PNA1-E8 and PNA2-E8, which were simultaneously coloaded in the particles following the same trapping protocol.

The loading value (calculated as the mass of the oligonucleotides PNA1-E8 + PNA2-E8 divided by the total mass of the PNAs + Si nanoparticles) was comparable to that found for a single-PNA loading ($\sim 17\%$). Release of PNA payloads was carried out in PBS, pH 7.4 at 37° over 24 h. The presence of both species in the solution was confirmed by UPLC-ESI-MS analysis of the supernatant, which demonstrated that after the first 2 h both PNAs had already started to be released (Figure S14, SI). This is important because porous silicon nanoparticles loaded with a combination of PNA-based therapeutics may enable synergistic strategies targeted to multiple biological pathways at once. Next, to demonstrate the potential of our formulation in drug delivery applications, we decided to investigate cell internalization of calcium silicate-capped pSiNP-PNA complexes and their ability to recognize and silence cognate microRNA targets. In this study, the PNA sequences PNA1, PNA2, and PNA3 were selected for their potential as anti-miR therapeutics in the context of cystic fibrosis, an autosomal recessive genetic disease deriving from malfunctioning of cystic fibrosis transmembrane conductance regulator (CFTR) protein. Inhibition of specific microRNAs involved in the regulation of the CFTR gene has been proposed as a potential therapeutic approach.^{41–43,46,47} For this application, we set out to test a neutral PNA payload because that represents the most challenging one to internalize in cells. As mentioned earlier in the text, the lack of charge in the canonical PNA backbone results in very poor cellular internalization properties. Conversely, positively charged PNAs




Figure 3. Investigation of cellular uptake and microRNA silencing of PNA 1, PNA 2, and PNA 3 trapped into pSiNPs. (A) Schematic drawing of the three distinct pSiNPs-PNA complexes tested in biological assays. (B) Flow cytometry graphs of untreated IB3–1 cells (gray) and IB3–1 cells treated with doses of pSiNPs corresponding to 4 μ M PNA (red). The fluorescent signal derives from the rhodamine B tag of the PNA payloads. (C) Internalization evaluated using BioStation IM (Nikon, Minato, Tokyo, Japan). Cells were either untreated (a) or treated with pSiNPs (b), only PNA1 (c), or pSiNP-PNA1 complexes (d). Pictures are presented as a merger of live, DAPI, and TRITC images. Higher-magnification images showing the cellular distribution of PNA when using pSiNP-PNA1 complexes are obtained as a merger of live and TRITC images (e–g). (D) Relative microRNA expression evaluated by reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) for miR-335, miR-101, and miR-145 in IB3–1 cells treated with pSiNPs carrying PNA 1 anti-miR-335, PNA 2 anti-miR-101, and PNA 3 anti-miR-145, respectively (mean \pm SEM, $n = 4$).

have been shown to display quite effective cell internalization due to interaction with the negatively charged cell membrane. Neutral PNAs are also the most difficult to noncovalently load into inorganic nanoparticles, such as pSiNPs, because any method based on the use of electrostatic interactions is not feasible. In contrast, negatively charged PNAs can be integrated in nanoparticle systems relying on the variety of methods available for DNA or RNA oligonucleotides.

Motivated by these arguments, we prepared a set of pSiNPs loaded with PNA1, PNA2, and PNA3, respectively, following the salt-based trapping method established above (Figure 3A). In this case, PNA strands were synthesized with rhodamine B (Rho) conjugated at one terminus, which allowed for obtaining fluorescent PNAs useful for fluorescence-based cell internalization studies. Loading into pSiNPs was performed according to the aforementioned protocol and gave analogous loading

values. Cellular uptake of the three different pSiNP-PNA complexes was studied *in vitro* using a human bronchial epithelial IB3–1 cell line as a cellular model. IB3–1 cells were incubated for 24 h with a concentration of nanoparticles that, based on the calculated loading value, translated in either a 2×10^{-6} M or a 4×10^{-6} M dose of PNA (PNA1, PNA2, PNA3, respectively). Following treatment, cellular internalization was evaluated by means of fluorescence-activated cell sorting (FACS) analysis, which showed effective internalization of the pSiNP-PNA complexes in all three cases based on the fluorescence signal due to rhodamine B (Figures 3B and S15 and S16, SI). Internalization of pSiNP-PNA complexes and delivery of PNA were further studied by imaging living cultured cells by means of a BioStation IM (Nikon, Minato, Tokyo, Japan). A representative set of results is shown in Figure 3C. Neither intracellular uptake nor PNA distributed in the cytoplasm could be observed in cells cultured with only PNA1 not encapsulated in pSiNPs (Figure 3C, panel c). On the contrary, almost all the cells cultured in the presence of pSiNP-PNA complexes displayed internalization and distribution of PNA in the cytoplasm (Figure 3C, panels d–g). A complete set of results obtained for the different pSiNP-PNA1, pSiNP-PNA2, and pSiNP-PNA3 complexes is reported in Figure S17 in the SI.

The ability of each PNA sequence released in the cytosol to bind and silence its cognate target microRNA was then measured by quantitative reverse transcription polymerase chain reaction (RT-qPCR). Incubation of independent samples of IB3–1 cells with each of the three different pSiNP-PNA complexes, respectively, led to a reduction of the expression (bioavailability) of the cognate microRNA target of ~50% in the case of miR-335 and miR-101, and of ~30% in the case of miR-145, relatively to untreated control samples. This demonstrates the high versatility of our approach in terms of inducible biological effect. Different PNA sequences targeting a pool of diverse microRNAs were all efficiently delivered to cultured epithelial cells and provided silencing of the desired, specific microRNA target. These results also suggest that even the simplest formats of calcium silicate-capped pSiNP-PNA complexes, i.e., bearing no surface functionalization with targeting ligands or polymer coatings and encapsulating a neutral PNA, are effectively uptaken by cells *in vitro*, and the released PNA payload in the cytosol can bind to and silence its target complementary RNA sequence.

In conclusion, we have demonstrated that PNA can be efficiently loaded into porous silicon nanoparticles following a simple, rapid approach based on calcium silicate trapping. The versatile chemistry of PNA allows for synthesizing oligonucleotides with custom net charge, and this can be used to optimize the efficiency of the trapping process. We have shown that calcium silicate trapping is compatible with both a negative, positive, and neutral PNA payload, and that charged PNAs can be encapsulated with loading values of ~30 nmol/mg pSi and with an efficiency of >90%. The charge of the PNA payload then determines the release kinetics of the nanoparticle system, with the release rate increasing from a neutral PNA payload (slowest release) to a negative PNA payload (fastest release).

This hints at the possibility to modulate the temporal delivery window of a specific PNA payload by playing on its chemical nature, which may be useful for both therapeutic and synthetic biology applications. The encapsulation of the eight arginine PNA (PNA-R8) into Ca-pSiNPs suggests that other positively charged payloads can be easily incorporated into

pSiNPs, which is ideal for minimizing the typical cytotoxicity associated with cationic drugs.^{48–50} In addition, using a calcium silicate-based approach for encapsulation of negatively charged payloads, such as siRNA or other therapeutic oligonucleotides, allows for bypassing the need for cationic polymers that are often proposed for loading anionic payloads in nanoparticle carriers through electrostatic interaction and that raise concern for their potential cytotoxicity.^{35,40,51} pSiNPs loaded with neutral PNA payloads successfully delivered their cargo in a model cell line relevant to cystic fibrosis and enabled silencing of three specific target microRNAs. Delivery of CFTR-upregulating anti-miRNA PNAs can support new therapeutic strategies for the treatment of cystic fibrosis.^{52,53} These results all demonstrate a strategy for formulating PNA into pSiNPs for therapeutic applications in precision medicine. Further engineering of the nanoparticle carrier, including functionalization with targeting elements, such as peptides, and/or surface PEGylation, and rationalization of the PNA payload, e.g., combining differently charged PNAs in the same nanoparticle to achieve staggered delivery in time, will help expand the applicability window and foster the therapeutic uses of PNA-pSiNP complexes as nanomedicine formulations.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acsbmaterials.1c00431>.

Description of the materials and methods and results related to PNA characterization, pSiNPs fabrication, release studies, cellular uptake assay, and coloaded assay (PDF)

■ AUTHOR INFORMATION

Corresponding Author

Alessandro Bertucci – Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, 43124 Parma, Italy; orcid.org/0000-0003-4842-9909; Email: alessandro.bertucci@unipr.it

Authors

Martina Neri – Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, 43124 Parma, Italy

Jinyoung Kang – Department of Nanoengineering, University of California San Diego, La Jolla, California 92093, United States; Present Address: Jinyoung Kang- McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA

Jonathan M. Zuidema – Department of Chemistry and Biochemistry and Department of Neurosciences, University of California San Diego, La Jolla, California 92093, United States; orcid.org/0000-0003-2258-0045

Jessica Gasparello – Department of Life Sciences and Biotechnology, University of Ferrara, 44121 Ferrara, Italy

Alessia Finotti – Department of Life Sciences and Biotechnology, University of Ferrara, 44121 Ferrara, Italy

Roberto Gambari – Department of Life Sciences and Biotechnology, University of Ferrara, 44121 Ferrara, Italy

Michael J. Sailor – Department of Chemistry and Biochemistry, University of California San Diego, La Jolla,

California 92093, United States; orcid.org/0000-0002-4809-9826

Roberto Corradini – Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, 43124 Parma, Italy; orcid.org/0000-0002-8026-0923

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acsbmaterials.1c00431>

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Notes

MJS is a scientific founder, a member of the board of directors, and holds an equity interest in Spinnaker Biosciences, Inc., and Cend Therapeutics. He also has a financial interest (as a consultant, shareholder, scientific advisor, and/or board member) with Beijing ITEC Technologies, Illumina, Matrix Technologies, NanoVision Bio, Pacific Integrated Energy, TruTag Technologies, and Well-Healthcare Technologies. MJS is a Guest Professor at Zhejiang University, China. Although one or more of the grants that supported this research has been identified for conflict of interest management based on the overall scope of the project and its potential benefit to these companies, the research findings included in this particular publication may not necessarily relate to their interests. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies.

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work has been partially funded by the European Commission through a MSCA-RISE Project Nano Oligomed (grant no. 778133) and from the NSF (grant No. CBET-1603177) and the UC San Diego Materials Research Science and Engineering Center (UCSD MRSEC) (grant No. DMR-2011924). This research benefited from equipment and core facilities provided by the COMP-HUB Initiative of the Department of Chemistry, Life Sciences and Environmental Sustainability of the University of Parma and funded by the “Departments of Excellence” program of the Italian Ministry for Education, University and Research (MIUR, 2018-2022) and the San Diego Nanotechnology Infrastructure (SDNI) of UCSD, a member of the National Nanotechnology Coordinated Infrastructure, which is supported by the National Science Foundation (grant no. ECCS-1542148). R.C. and R.G. acknowledge partial support from Fondazione Fibrosi Cistica (FFC#7/2018). This project received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 704120 “MIRNANO” (A.B.).

REFERENCES

- (1) Saabach, J.; Sabale, P. M.; Winssinger, N. Peptide Nucleic Acid (PNA) and Its Applications in Chemical Biology, Diagnostics, and Therapeutics. *Curr. Opin. Chem. Biol.* **2019**, *52*, 112–124.
- (2) Cheng, C. J.; Bahal, R.; Babar, I. A.; Pincus, Z.; Barrera, F.; Liu, C.; Svoronos, A.; Braddock, D. T.; Glazer, P. M.; Engelman, D. M.; Saltzman, W. M.; Slack, F. J. MicroRNA Silencing for Cancer Therapy Targeted to the Tumour Microenvironment. *Nature* **2015**, *518* (7537), 107–110.

- (3) Nielsen, P. E.; Haaïma, G. Peptide Nucleic Acid (PNA). A DNA Mimic with a Pseudopeptide Backbone. *Chem. Soc. Rev.* **1997**, *26* (2), 73–78.
- (4) Nielsen, P. E. PNA Technology. *Mol. Biotechnol.* **2004**, *26* (3), 233–248.
- (5) Nielsen, P. E. Peptide Nucleic Acids (PNA) in Chemical Biology and Drug Discovery. *Chem. Biodiversity* **2010**, *7* (4), 786–804.
- (6) Saabach, J.; Sabale, P. M.; Winssinger, N. Peptide Nucleic Acid (PNA) and Its Applications in Chemical Biology, Diagnostics, and Therapeutics. *Curr. Opin. Chem. Biol.* **2019**, *52*, 112–124.
- (7) Volpi, S.; Cancelli, U.; Neri, M.; Corradini, R. Multifunctional Delivery Systems for Peptide Nucleic Acids. *Pharmaceuticals* **2021**, *14* (1), 14–31.
- (8) Zorko, M.; Langel, U. Cell-Penetrating Peptides: Mechanism and Kinetics of Cargo Delivery. *Adv. Drug Delivery Rev.* **2005**, *57* (4), 529–545.
- (9) Pooga, M.; Soomets, U.; Hällbrink, M.; Valkna, A.; Saar, K.; Rezaei, K.; Kahl, U.; Hao, J. X.; Xu, X. J.; Wiesenfeld-Hallin, Z.; Hökfelt, T.; Bartfai, T.; Langel, U. Cell Penetrating PNA Constructs Regulate Galanin Receptor Levels and Modify Pain Transmission in Vivo. *Nat. Biotechnol.* **1998**, *16* (9), 857–861.
- (10) Tan, X.; Bruchez, M. P.; Armitage, B. A. Closing the Loop: Constraining TAT Peptide by GPNA Hairpin for Enhanced Cellular Delivery of Biomolecules. *Bioconjugate Chem.* **2018**, *29* (9), 2892–2898.
- (11) Ndeboko, B.; Ramamurthy, N.; Lemamy, G. J.; Jamard, C.; Nielsen, P. E.; Cova, L. Role of Cell-Penetrating Peptides in Intracellular Delivery of Peptide Nucleic Acids Targeting Hepadnaviral Replication. *Mol. Ther.–Nucleic Acids* **2017**, *9*, 162–169.
- (12) Cheng, C. J.; Bahal, R.; Babar, I. A.; Pincus, Z.; Barrera, F.; Liu, C.; Svoronos, A.; Braddock, D. T.; Glazer, P. M.; Engelman, D. M.; Saltzman, W. M.; Slack, F. J. MicroRNA Silencing for Cancer Therapy Targeted to the Tumour Microenvironment. *Nature* **2015**, *518* (7537), 107–110.
- (13) Ghavami, M.; Shiraishi, T.; Nielsen, P. E. Enzyme-Triggered Release of the Antisense Octaarginine-PNA Conjugate from Phospholipase A2 Sensitive Liposomes. *ACS Appl. Bio Mater.* **2020**, *3* (2), 1018–1025.
- (14) Ringhieri, P.; Avitabile, C.; Saviano, M.; Morelli, G.; Romanelli, A.; Accardo, A. The Influence of Liposomal Formulation on the Incorporation and Retention of PNA Oligomers. *Colloids Surf., B* **2016**, *145*, 462–469.
- (15) Avitabile, C.; Accardo, A.; Ringhieri, P.; Morelli, G.; Saviano, M.; Montagner, G.; Fabbri, E.; Gallerani, E.; Gambari, R.; Romanelli, A. Incorporation of Naked Peptide Nucleic Acids into Liposomes Leads to Fast and Efficient Delivery. *Bioconjugate Chem.* **2015**, *26* (8), 1533–1541.
- (16) Cheng, C. J.; Saltzman, W. M. Polymer Nanoparticle-Mediated Delivery of MicroRNA Inhibition and Alternative Splicing. *Mol. Pharmaceutics* **2012**, *9* (5), 1481–1488.
- (17) Babar, I. A.; Cheng, C. J.; Booth, C. J.; Liang, X.; Weidhaas, J. B.; Saltzman, W. M.; Slack, F. J. Nanoparticle-Based Therapy in an in Vivo MicroRNA-155 (MiR-155)-Dependent Mouse Model of Lymphoma. *Proc. Natl. Acad. Sci. U. S. A.* **2012**, *109* (26), 1695–1704.
- (18) Gupta, A.; Quijano, E.; Liu, Y.; Bahal, R.; Scanlon, S. E.; Song, E.; Hsieh, W. C.; Braddock, D. E.; Ly, D. H.; Saltzman, W. M.; Glazer, P. M. Anti-Tumor Activity of MiniPEG- γ -Modified PNAs to Inhibit MicroRNA-210 for Cancer Therapy. *Mol. Ther.–Nucleic Acids* **2017**, *9*, 111–119.
- (19) McNeer, N. A.; Chin, J. Y.; Schleifman, E. B.; Fields, R. J.; Glazer, P. M.; Saltzman, W. M. Nanoparticles Deliver Triplex-Forming PNAs for Site-Specific Genomic Recombination in CD34+ Human Hematopoietic Progenitors. *Mol. Ther.* **2011**, *19* (1), 172–180.
- (20) Fang, H.; Zhang, K.; Shen, G.; Wooley, K. L.; Taylor, J.-S. A. Cationic Shell-Cross-Linked Knedel-like (CSCK) Nanoparticles for Highly Efficient PNA Delivery. *Mol. Pharmaceutics* **2009**, *6* (2), 615–626.

- (21) Shrestha, R.; Shen, Y.; Pollack, K. A.; Taylor, J.-S. A.; Wooley, K. L. Dual Peptide Nucleic Acid- and Peptide-Functionalized Shell Cross-Linked Nanoparticles Designed to Target mRNA toward the Diagnosis and Treatment of Acute Lung Injury. *Bioconjugate Chem.* **2012**, *23* (3), 574–585.
- (22) Ryoo, S.-R.; Lee, J.; Yeo, J.; Na, H.-K.; Kim, Y.-K.; Jang, H.; Lee, J. H.; Han, S. W.; Lee, Y.; Kim, V. N.; Min, D.-H. Quantitative and Multiplexed MicroRNA Sensing in Living Cells Based on Peptide Nucleic Acid and Nano Graphene Oxide (PANGO). *ACS Nano* **2013**, *7* (7), 5882–5891.
- (23) Gaillard, C.; Girard, H. A.; Falck, C.; Paget, V.; Simic, V.; Ugolin, N.; Bergonzo, P.; Chevillard, S.; Arnault, J. C. Peptide Nucleic Acid–Nanodiamonds: Covalent and Stable Conjugates for DNA Targeting. *RSC Adv.* **2014**, *4* (7), 3566–3572.
- (24) Hwang, D. W.; Kim, H. Y.; Li, F.; Park, J. Y.; Kim, D.; Park, J. H.; Han, H. S.; Byun, J. W.; Lee, Y.-S.; Jeong, J. M.; Char, K.; Lee, D. S. Vivo Visualization of Endogenous MiR-21 Using Hyaluronic Acid-Coated Graphene Oxide for Targeted Cancer Therapy. *Biomaterials* **2017**, *121*, 144–154.
- (25) Liao, X.; Wang, Q.; Ju, H. A Peptide Nucleic Acid-Functionalized Carbon Nitride Nanosheet as a Probe for in Situ Monitoring of Intracellular MicroRNA. *Analyst* **2015**, *140* (12), 4245–4252.
- (26) Bertucci, A.; Lülff, H.; Septiadi, D.; Manicardi, A.; Corradini, R.; De Cola, L. Intracellular Delivery of Peptide Nucleic Acid and Organic Molecules Using Zeolite-L Nanocrystals. *Adv. Healthcare Mater.* **2014**, *3* (11), 1812–1817.
- (27) Bertucci, A.; Prasetyanto, E. A.; Septiadi, D.; Manicardi, A.; Brognara, E.; Gambari, R.; Corradini, R.; De Cola, L. Combined Delivery of Temozolomide and Anti-MiR221 PNA Using Mesoporous Silica Nanoparticles Induces Apoptosis in Resistant Glioma Cells. *Small* **2015**, *11* (42), 5687–5695.
- (28) Ma, X.; Devi, G.; Qu, Q.; Toh, D. F. K.; Chen, G.; Zhao, Y. Intracellular Delivery of Antisense Peptide Nucleic Acid by Fluorescent Mesoporous Silica Nanoparticles. *Bioconjugate Chem.* **2014**, *25* (8), 1412–1420.
- (29) Canham, L. T. Bioactive Silicon Structure Fabrication Through Nanoetching Techniques. *Adv. Mater.* **1995**, *7*, 1033–1037.
- (30) Canham, L. T. Silicon Quantum Wire Array Fabrication by Electrochemical. *Appl. Phys. Lett.* **1990**, *57*, 1046–1048.
- (31) Park, J. H.; Gu, L.; Von Maltzahn, G.; Ruoslahti, E.; Bhatia, S. N.; Sailor, M. J. Biodegradable Luminescent Porous Silicon Nanoparticles for in Vivo Applications. *Nat. Mater.* **2009**, *8* (4), 331–336.
- (32) Qin, Z.; Joo, J.; Gu, L.; Sailor, M. J. Size Control of Porous Silicon Nanoparticles by Electrochemical Perforation Etching. *Part. Part. Syst. Charact.* **2014**, *31*, 252–256.
- (33) Beavers, K. R.; Mares, J. W.; Swartz, C. M.; Zhao, Y.; Weiss, S. M.; Duvall, C. L. In Situ Synthesis of Peptide Nucleic Acids in Porous Silicon for Drug Delivery and Biosensing. *Bioconjugate Chem.* **2014**, *25* (7), 1192–1197.
- (34) Beavers, K. R.; Werfel, T. A.; Shen, T.; Kavanaugh, T. E.; Kilchrist, K. V.; Mares, J. W.; Fain, J. S.; Wiese, C. B.; Vickers, K. C.; Weiss, S. M.; Duvall, C. L. Porous Silicon and Polymer Nanocomposites for Delivery of Peptide Nucleic Acids as Anti-MicroRNA Therapies. *Adv. Mater.* **2016**, *28* (36), 7984–7992.
- (35) Kang, J.; Joo, J.; Kwon, E. J.; Skalak, M.; Hussain, S.; She, Z. G.; Ruoslahti, E.; Bhatia, S. N.; Sailor, M. J. Self-Sealing Porous Silicon-Calcium Silicate Core–Shell Nanoparticles for Targeted siRNA Delivery to the Injured Brain. *Adv. Mater.* **2016**, *28* (36), 7962–7969.
- (36) Bertucci, A.; Kim, K. H.; Kang, J.; Zuidema, J. M.; Lee, S. H.; Kwon, E. J.; Kim, D.; Howell, S. B.; Ricci, F.; Ruoslahti, E.; Jang, H. J.; Sailor, M. J. Tumor-Targeting, MicroRNA-Silencing Porous Silicon Nanoparticles for Ovarian Cancer Therapy. *ACS Appl. Mater. Interfaces* **2019**, *11* (27), 23926–23937.
- (37) Zuidema, J. M.; Bertucci, A.; Kang, J.; Sailor, M. J.; Ricci, F. Hybrid Polymer/Porous Silicon Nanofibers for Loading and Sustained Release of Synthetic DNA-Based Responsive Devices. *Nanoscale* **2020**, *12* (4), 2333–2339.
- (38) Zuidema, J. M.; Dumont, C. M.; Wang, J.; Batchelor, W. M.; Lu, Y.-S.; Kang, J.; Bertucci, A.; Ziebarth, N. M.; Shea, L. D.; Sailor, M. J. Porous Silicon Nanoparticles Embedded in Poly(Lactic-Co-Glycolic Acid) Nanofiber Scaffolds Deliver Neurotrophic Payloads to Enhance Neuronal Growth. *Adv. Funct. Mater.* **2020**, *30* (25), 2002560.
- (39) Kim, B.; Sun, S.; Varner, J. A.; Howell, S. B.; Ruoslahti, E.; Sailor, M. J. Securing the Payload, Finding the Cell, and Avoiding the Endosome: Peptide-Targeted, Fusogenic Porous Silicon Nanoparticles for Delivery of siRNA. *Adv. Mater.* **2019**, *31* (35), 1902952.
- (40) Kim, B.; Pang, H.-B.; Kang, J.; Park, J.-H.; Ruoslahti, E.; Sailor, M. J. Immunogene Therapy with Fusogenic Nanoparticles Modulates Macrophage Response to Staphylococcus Aureus. *Nat. Commun.* **2018**, *9* (1), 1969.
- (41) Fabbri, E.; Tamanini, A.; Jakova, T.; Gasparello, J.; Manicardi, A.; Corradini, R.; Finotti, A.; Borgatti, M.; Lampronti, I.; Munari, S.; Dechecchi, M. C.; Cabrini, G.; Gambari, R. Treatment of Human Airway Epithelial Calu-3 Cells with a Peptide-Nucleic Acid (PNA) Targeting the MicroRNA MiR-101–3p Is Associated with Increased Expression of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene. *Eur. J. Med. Chem.* **2021**, *209*, 112876.
- (42) Fabbri, E.; Tamanini, A.; Jakova, T.; Gasparello, J.; Manicardi, A.; Corradini, R.; Sabbioni, G.; Finotti, A.; Borgatti, M.; Lampronti, I.; Munari, S.; Dechecchi, M. C.; Cabrini, G.; Gambari, R. A Peptide Nucleic Acid against MicroRNA MiR-145–5p Enhances the Expression of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) in Calu-3 Cells. *Molecules* **2018**, *23* (1), 71.
- (43) Tamanini, A.; Fabbri, E.; Jakova, T.; Gasparello, J.; Manicardi, A.; Corradini, R.; Finotti, A.; Borgatti, M.; Lampronti, I.; Munari, S.; Dechecchi, M. C.; Cabrini, G.; Gambari, R. A Peptide-Nucleic Acid Targeting MiR-335–5p Enhances Expression of Cystic Fibrosis Transmembrane Conductance Regulator Gene with the Possible Involvement of the CFTR Scaffolding Protein NHERF1. *Biomedicines* **2021**, *9* (2), 117.
- (44) Segal, E.; Perelman, L. A.; Cunin, F.; Di Renzo, F.; Devoisselle, J.-M.; Li, Y. Y.; Sailor, M. J. Confinement of Thermoresponsive Hydrogels in Nanostructured Porous Silicon Dioxide Templates. *Adv. Funct. Mater.* **2007**, *17* (7), 1153–1162.
- (45) Lülff, H.; Bertucci, A.; Septiadi, D.; Corradini, R.; De Cola, L. Multifunctional Inorganic Nanocontainers for DNA and Drug Delivery into Living Cells. *Chem. - Eur. J.* **2014**, *20* (35), 10900–10904.
- (46) Sonnevile, F.; Ruffin, M.; Coraux, C.; Rousselet, N.; Le Rouzic, P.; Blouquit-Laye, S.; Corvol, H.; Tabary, O. MicroRNA-9 Downregulates the ANO1 Chloride Channel and Contributes to Cystic Fibrosis Lung Pathology. *Nat. Commun.* **2017**, *8* (1), 710.
- (47) Bardin, P.; Sonnevile, F.; Corvol, H.; Tabary, O. Emerging MicroRNA Therapeutic Approaches for Cystic Fibrosis. *Front. Pharmacol.* **2018**, *9*, 1113.
- (48) Piras, A. M.; Maisetta, G.; Sandreschi, S.; Gazzarri, M.; Bartoli, C.; Grassi, L.; Esin, S.; Chiellini, F.; Batoni, G. Chitosan Nanoparticles Loaded with the Antimicrobial Peptide Temporin B Exert a Long-Term Antibacterial Activity in Vitro against Clinical Isolates of Staphylococcus Epidermidis. *Front. Microbiol.* **2015**, *6*, 372.
- (49) Almaaytah, A.; Mohammed, G. K.; Abualhajja, A.; Al-Balas, Q. Development of Novel Ultrashort Antimicrobial Peptide Nanoparticles with Potent Antimicrobial and Antibiofilm Activities against Multidrug-Resistant Bacteria. *Drug Des., Dev. Ther.* **2017**, *11*, 3159–3170.
- (50) Kwon, E. J.; Skalak, M.; Bertucci, A.; Braun, G.; Ricci, F.; Ruoslahti, E.; Sailor, M. J.; Bhatia, S. N. Porous Silicon Nanoparticle Delivery of Tandem Peptide Anti-Infectives for the Treatment of Pseudomonas Aeruginosa Lung Infections. *Adv. Mater.* **2017**, *29*, 1701527.
- (51) Verma, A.; Stellacci, F. Effect of Surface Properties on Nanoparticle-Cell Interactions. *Small* **2010**, *6*, 12–21.
- (52) McKiernan, P. J.; Cunningham, O.; Greene, C. M.; Cryan, S.-A. Targeting MiRNA-Based Medicines to Cystic Fibrosis Airway

Epithelial Cells Using Nanotechnology. *Int. J. Nanomed.* **2013**, *8*, 3907–3915.

(53) Comegna, M.; Conte, G.; Falanga, A. P.; Marzano, M.; Cenera, G.; Di Lullo, A. M.; Amato, F.; Borbone, N.; D'Errico, S.; Ungaro, F.; d'Angelo, I.; Oliviero, G.; Castaldo, G. Assisting PNA Transport through Cystic Fibrosis Human Airway Epithelia with Biodegradable Hybrid Lipid-Polymer Nanoparticles. *Sci. Rep.* **2021**, *11* (1), 6393.